[18F]HX4 PET/CT Imaging for Detection of Hypoxia

NCT ID: NCT02976883

Last Updated: 2019-01-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2017-07-25

Brief Summary

The aim of this study is to investigate the radiotracer [18F]HX4 for non-invasive detection of hypoxia in patients with head and neck, or lung cancer. Each participant will undergo a diagnostic [18F]HX4 PET/CT scan before beginning radiotherapy treatment. Patient follow up data will be collected from routine appointments, and analysed with the hypoxia scan results to assess whether [18F]HX4 PET/CT scanning can predict patient outcome from radiotherapy treatment.

Conditions

Head and Neck Cancer; Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

[18F]HX4 diagnostic PET/CT scan

\[18F\]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.

Group Type: EXPERIMENTAL

[18F]HX4 diagnostic PET/CT scan

Intervention Type: OTHER

Single intravenous injection of \[18F\]HX4 and PET/CT scan

Interventions

[18F]HX4 diagnostic PET/CT scan

Single intravenous injection of \[18F\]HX4 and PET/CT scan

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients with:

1. biopsy proven non-small cell carcinoma of the lung >2.5 cm in size with any T and N status but M0 who have elected to undergo radical radiotherapy or chemo-radiotherapy with curative intent or

2. squamous cell carcinoma of the upper aerodigestive tract with a primary tumour or nodal mass >2. 5 cm in size, with any T and N status but M0 who have elected to undergo radical radiotherapy or chemo-radiotherapy with curative intent.

• Participant must be willing and able to give informed consent for participation in the study.
• Patients must be 18 years old or above.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
• Have normal renal function, defined by creatinine clearance of >60 mL/min.
• Able to remain still in the supine position on the scanner bed for the 40 minute duration of the examination.
• Able (in the Investigators opinion) and willing to comply with all study requirements.
• Willing to allow his or her General Practitioner and hospital consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria

• Patients who are scheduled for surgery prior to radiotherapy will not be included.
• Female participant who is pregnant, lactating or planning pregnancy during the course of the study.
• Chronic kidney disease stage III or worse, as defined by the NKF clinical practice guidelines (GFR <60 mL/min per 1.73 m3 for 3 months or more).
• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of involvement in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• Participants who have been involved in another research study involving an investigational product in the past 12 weeks.
• Previous surgery or radiotherapy to the upper aerodigestive tract or lung, which in the opinion of the Investigators could compromise the data.
• Previous cancer diagnosis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nottingham University Hospitals NHS Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alan C Perkins, PhD

Role: STUDY_CHAIR

Nottingham University Hospitals NHS Trust

Locations

Nottingham University Hospitals NHS Trust

Nottingham, Nottinghamshire, United Kingdom

Countries

United Kingdom

Other Identifiers

13MP003

Identifier Type: -

Identifier Source: org_study_id